This review examines the various aspects of senescence in prostate cancer development, ranging from DNA damage- and oncogene-induced senescence (p53/p21, PTEN/p16, and RAS/MYC) to treatment-induced senescence following androgen deprivation, radiotherapy, and chemotherapy. The gene discussed is TP53; the disease is prostate carcinoma.